iCAD (NASDAQ:ICAD) released its quarterly earnings data on Thursday. The technology company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.01, Morningstar.com reports. The firm had revenue of $7.33 million during the quarter, compared to the consensus estimate of $6.69 million. iCAD had a negative net margin of 36.24% and a negative return on equity of 54.45%.
Shares of ICAD traded down $0.09 during midday trading on Friday, hitting $6.74. 138,773 shares of the stock traded hands, compared to its average volume of 154,208. iCAD has a 1-year low of $2.42 and a 1-year high of $7.45. The company has a market capitalization of $129.83 million, a price-to-earnings ratio of -17.74 and a beta of 1.04. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.47 and a quick ratio of 1.33. The company’s 50 day simple moving average is $6.42.
Separately, ValuEngine downgraded shares of iCAD from a “buy” rating to a “hold” rating in a report on Thursday.
iCAD Company Profile
iCAD, Inc provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy.
Further Reading: Using other technical indicators with support levels
Receive News & Ratings for iCAD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iCAD and related companies with MarketBeat.com's FREE daily email newsletter.